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The program intends to drive the required paradigm shift 
in toxicology toward animal-free, mechanism-based inte-
grated approaches for chemical safety assessment (Leist 
et al. 2008; NRC 2007; Rovida et al. 2015a, b; Sauer et al. 
2015; Scholz et al. 2013). Bennard van Ravenzwaay coor-
dinating the contribution of BASF as a consortium partner 
pointed out during his inaugural lecture that “this pro-
ject is rather about regulatory risk assessment than about 
methods.”
The focus of this 6-year project lies on repeated dose 
systemic toxicity involving liver, kidney, lung, and the 
nervous system, as well as on developmental/reproductive 
toxicity (Hengstler et al. 2012). Particular attention will be 
paid to the establishment of pragmatic read-across proce-
dures incorporating mechanistic and toxicokinetic knowl-
edge as well as hazard and risk assessment strategies for 
chemicals with minimal background information (Basket-
ter et al. 2012; Carrio et al. 2015; Patlewicz et al. 2014; van 
der Burg et al. 2015). EU-ToxRisk will use its resources 
in order to establish in 3 years’ time a novel read-across 
approach in Europe, especially fit for evaluating REACH 
compounds. A quantitatively structured read-across system 
will use existing data as well as providing new informa-
tion, including data from high-throughput transcriptomics 
(Pallocca et al. 2016; Rempel et al. 2015; Grinberg et al. 
2014; Jennings et al. 2013; Schaap et al. 2015), high-con-
tent imaging of cell stress pathways (Wink et al. 2014; van 
Vliet et al. 2014; Jennings 2013) in vitro systems (Godoy 
et al. 2013; Krug et al. 2013), and mathematical modeling 
to extrapolate to the in vivo situation (Ghallab et al. 2016; 
Schliess et al. 2014). Moreover, EU-ToxRisk intends to 
establish a biological read-across approach, adding biologi-
cal descriptors to toxicological and chemical descriptors 
(EU-ToxRisk 2015; Zhu et al. 2016). Due to the potential 
of chemical and biological read-across approaches and 
Abstract The integrated European project, EU-ToxRisk, 
proudly sees itself as “flagship” exploring new alterna-
tive-to-animal approaches to chemical safety evaluation. 
It promotes mechanism-based toxicity testing and risk 
assessment according to the principles laid down for toxi-
cology for the twenty-first century. The project was offi-
cially launched in January 2016 with a kickoff meeting 
in Egmond aan Zee, the Netherlands. Over 100 scientists 
representing academia and industry as well as regulatory 
authorities attended the inaugural meeting. The project 
will integrate advances in in vitro and in silico toxicol-
ogy, read-across methods, and adverse outcome pathways. 
EU-ToxRisk will continue to make use of the case study 
strategy deployed in SEURAT-1, a FP7 initiative ended in 
December 2015. Even though the development of new non-
animal methods is one target of EU-ToxRisk, the project 
puts special emphasis on their acceptance and implementa-
tion in regulatory contexts. This €30 million Horizon 2020 
project involves 38 European partners and one from the 
USA. EU-ToxRisk aims at the “development of a new way 
of risk assessment.”
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the importance of good practice guidelines to this field, 
EU-ToxRisk’s first workshop on February 26 in Brus-
sels presented the new “Good Read-Across Practice guid-
ance” (Ball et al. 2016) and other relevant initiatives among 
stakeholders.
EU-ToxRisk coordinator Bob van de Water from the 
University of Leiden introduced the mission. The overall 
EU-ToxRisk mission is to develop a quantitative adverse 
outcome pathway (qAOP) concept for regulatory purposes 
integrating relevant in vitro and in silico technologies 
required for the assessment of chemical safety in humans 
(Leist et al. 2014; Luechtefeld et al. 2015; Muller et al. 
2015; Jennings 2013). The concept of EU-ToxRisk was 
commented by Magdalini Sachana (OECD), an external 
advisor of the project with the words: “I was delighted to 
see that adverse outcome pathways (AOPs) and integrated 
approaches to testing and assessment (IATA) play a central 
role in almost all the work packages of the project (Tollef-
sen et al. 2014; Bal-Price et al. 2015; Gocht et al. 2015). I 
look forward receiving more information and outputs from 
the project.”
EU-ToxRisk already works on more than ten case stud-
ies, and the consortium partners will begin evaluating the 
predictivity of a battery of assays soon, using data-rich 
chemicals. Later, case studies will be established for less 
characterized new classes of compounds. The consortium 
has already established a task force, which will criti-
cally assess the robustness and applicability of the pro-
posed human cell model systems for these case studies. 
“The case studies with selected compounds will remain 
focused on adverse human consequences, i.e., provide rel-
evant concentration–response models, and tipping points 
of homeostasis in order to predict safe exposure levels” 
as to Carl Westmoreland (Unilever—EU-ToxRisk part-
ner) (Shah et al. 2015). “The importance of building toxi-
cokinetics and toxicodynamics within EU-ToxRisk for 
weight of evidence approaches in risk assessment” was 
emphasized by Derek Knight representing ECHA (Berg-
gren et al. 2015; Daston et al. 2015; Gocht et al. 2015). 
Regarding the case studies, Thomas Steger-Hartmann 
from Bayer HealthCare commented as an external advi-
sor of the project: “The well-organized and conducted 
kickoff meeting prepared the stage for an ambitious pro-
ject that has the potential to change existing safety assess-
ment paradigms. The backbone of the project plan are the 
case studies. A big part of the success of the project will 
depend on the thoughtful selection of test compounds, 
assay systems, and benchmark data for evaluation” (Jen-
nings et al. 2014).
Russell Thomas from the US EPA stated that “I was 
impressed with the enthusiasm of the scientists involved 
in the project and the willingness to move beyond basic 
research and to apply their science to practical, but 
important questions facing society in testing chemicals 
for human safety. There appears to be multiple points 
of intersection between the EU-ToxRisk project and the 
research being undertaken by the U.S. EPA (Shah et al. 
2015; Bouhifd et al. 2015; Kleinstreuer et al. 2014) in the 
National Center for Computational Toxicology (Liu et al. 
2015; Huang et al. 2014). Collaboration at these points of 
intersection would benefit both organizations and allow us 
to achieve much more together than in isolation. I look for-
ward to working with and advising the EU-ToxRisk pro-
ject. It is poised to have a significant impact on the way we 
evaluate chemicals for human safety.”
The excellent start of the project was helped by exten-
sive preparations by the scientific steering team and the 
coordinator of the project already in 2015, in order to 
optimize and refine information flow and work flow of the 
project. Due to the latter, a remarkable positive and enthu-
siastic atmosphere during the meeting was notable which 
is rather exceptional for a kickoff meeting of such a large-
scale project. The spirit of all participants of all fourteen 
work packages was remarkably optimistic and stimulating. 
If the project keeps up this level of dynamics and thrives, 
a lot is to be expected for the near future and the coming 
6 years.
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